The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies
|
|
- Esmond Dean
- 5 years ago
- Views:
Transcription
1 The benefit of in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies Matthew P. Goetz¹, Joyce O Shaughnessy², George W. Sledge Jr.³, Miguel Martin⁴, Yong Lin⁵, Tammy Forrester⁵, Colleen Mockbee⁵, Ian C. Smith⁵, Angelo Di Leo⁶, Stephen Johnston⁷ ¹Mayo Clinic, Rochester, MN; ²Baylor University Medical Center, Texas Oncology, US Oncology, Dallas TX; ³Stanford University, CA; ⁴Instituto De Investigacion Sanitaria Gregorio Maranon, Ciberonc, Geicam; Universidad Complutense, Madrid, Spain; ⁵Eli Lilly and Company, Indianapolis, IN; ⁶Hospital of Prato, Istituto Toscano Tumori, Prato, Italy; ⁷The Royal Marsden NHS Foundation Trust, London, UK
2 MONARCH 2 and 3 Study Design MONARCH 2 (N=669) MONARCH 3 (N=493) HR+, HER2- ABC Pre/peri-ᵃ or postmenopausal ET resistant: - Relapsed on neoadjuvant or on/within 1 yr of adjuvant ETᵇ - Progressed on first-line ET No chemo for MBC No more than 1 ET for MBC EGOS PS 1 HR+, HER2- ABC Postmenopausal Metastatic or locally recurrent disease with no prior systemic therapy in this setting If neoadjuvant or adjuvant ET administered, a diseasefree interval of > 12 months since completion of ET ECOG PS 1 2:1 2:1 ademaciclib: 150 mg c BID (continuous schedule) plus fulvestrant: 500 mg d placebo: BID (continuous schedule) plus fulvestrant: 500 mg d ademaciclib: 150 mg BID (continuous schedule) plus anastrozole: 1 mg or e letrozole: 2.5 mg QD placebo: BID (continuous schedule) plus anastrozole: 1 mg or e letrozole: 2.5 mg QD ᵃRequired to receive GnRH agonist ᵇMost patients entered after progressing while receiving prior ET, with only 8.8% who had disease that progressed within 1 year after completing adjuvant therapy ᶜDose reduced by protocol amendment in all new and ongoing patients from 200 mg to 150 mg BID after 178 patients enrolled ᵈFulvestrant administered per label ᵉPer physician choice: 79.1% received letrozole, 19.9% received anastrozole
3 MONARCH 2 and 3 PFS (ITT) MONARCH 2 Median PFS¹ Abemaciclib + fulvestrant: months (N=446) Placebo + fulvestrant: 9.27 months (N=223) HR, (95% CI, to 0.681) P< MONARCH 3 Median PFS² Abemaciclib + NSAI: Not reached (N=328) Placebo + NSAI: months (N=165) HR, (95% CI, to 0.723) P< Sledge GW Jr et al. J Clin Oncol. 2017;35(25): Goetz MP et al. J Clin Oncol. 2017;35(32):
4 Liver Metastases Baseline Liver Metastases - No Baseline Liver Metastases - Yes MONARCH 2 fulvestrant +/- median, months (n=331) median, months (n=164) median, months (n=115) median, 3.09 months (n=59) HR, (95%, Cl, to 0.713) HR, (95% Cl, to 0.644) median, NR (n=280) Median, months (n=135) median, months (n=48) median, 7.20 months (n=30) MONARCH 3 NSAI +/- HR, (95%, Cl, to 0.780) HR, (95% Cl, to 0.780) 1. Goetz MP et al. J Clin Oncol. 2017;35(32): Di Leo A et al. Annals of Oncology. 2017;28 (suppl_5): v605-v649
5 Progesterone Receptor Status Progesterone Receptor - Positive Progesterone Receptor - Negative MONARCH 2 fulvestrant +/- median, months (n=339) median, months (n=171) median, months (n=96) median, 7.43 months (n=44) HR, (95% Cl, to 0.743) HR, (95% Cl, to 0.797) median, NR (n=255) median, months (n=127) median, NR (n=70) median, 9.40 months (n=36) MONARCH 3 NSAI +/- HR, (95% Cl, to 0.842) HR, (95%, Cl, to 0.760)
6 Tumor Grade Tumor Grade Low/intermediate Tumor Grade High MONARCH 2 fulvestrant +/- median, months (n=233) median, months (n=112) median, months (n=109) median, 5.72 months (n=60) HR, (95%, Cl, to 0.860) HR, (95% Cl, to 0.706) median, NR (n=180) median, months (n=96) median, NR (n=64) median, 8.94 months (n=32) MONARCH 3 NSAI +/- HR, (95% Cl, to 0.916) HR, (95% Cl, to 0.733)
7 Conlusions These exploratory analyses over 1000 patients treated in MONARCH 2 and MONARCH 3 demonstrated that all subgroups benefited from the addition of to endocrine therapy Abemaciclib in combination with endocrine therapy offered the largest benefit (PFS and ORR) in patients with clinical characteristics that make the prognosis more concerning - The largest improvements were in patients with liver metastases, PgR-negative tumors, or high grade tumors In the first-line setting, for patients with a short TFI, a substantial improvement from the addition of to endocrine therapy was observed Further data are needed to inform treatment strategies for patients with more favorable baseline prognostic factors (e.g., bone-only, long TFI)
Metastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationHighlights of. Metastatic & Advanced Breast Cancer
Highlights of Metastatic & Advanced Breast Cancer 1 Financial Disclosure(s) I currently have or have had the following relevant financial relations to disclose: Speaker s Bureau: Novartis 2 Off Label Use
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationCancers du Sein Métastatiques
Cancers du Sein Métastatiques Véronique Diéras Journée Laurence Leroyer Rennes 18 mai 2018 Plan ESME Inhibiteurs CDK 4/6 RH+ Inhibiteurs PARP Anticorps drogue-conjugués Perspectives 2018-2019 ESME Time
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationHighlitghs in MBC First and second line endocrine treatments. Antonio Frassoldati Oncologia Clinica Ferrara
Highlitghs in MBC First and second line endocrine treatments Antonio Frassoldati Oncologia Clinica Ferrara Which clinical scenario have to face First line therapy with today? Untreated metastatic breast
More informationNeratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 5-year analysis of the phase III ExteNET trial
Oral presentation #149O Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 5-year analysis of the phase III ExteNET trial Miguel Martin, 1 Frankie A. Holmes, 2 Bent
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationClinical Spotlight Key Advances in Hormone Receptor Positive Breast Cancer: Updates From the 2018 Oncology Annual Meeting in Chicago
Clinical Spotlight Key Advances in Hormone Receptor Positive Breast Cancer: Updates From the 2018 Oncology Annual Meeting in Chicago Reference Slide Deck Abstract 1000 Abstract 1001 Abstract 1002 Abstract
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationVerzenio (abemaciclib) NEW PRODUCT SLIDESHOW
Verzenio (abemaciclib) NEW PRODUCT SLIDESHOW Introduction Brand name: Verzenio Generic name: Abemaciclib Pharmacological class: Kinase inhibitor Strength and Formulation: 50mg, 100mg, 150mg, 200mg; tabs
More informationPharmacology Updates in Breast Cancer Chris Vaklavas, M.D.
Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Assistant Professor Department of Medicine, Division of Hematology/Oncology University of Alabama at Birmingham NP2540M 1802 6th Avenue South
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationManagement of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers
Review Article Page 1 of 10 Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers Roger K. C. Ngan Department of Clinical Oncology, Queen Elizabeth
More informationSession Breast Cancer. Alessandra Fabi Il punto di vista dell esperto
Session Breast Cancer Alessandra Fabi Il punto di vista dell esperto Roma 6-7.10.2017 The Importance of Understanding What Disease to Treat Cejalvo et al, Cancer Res 2017 Skyline Chaging at evolution of
More informationDEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc
DEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc Revue des essais cliniques en cours et perspectives Dr Cristian Villanueva CHRU Besançon
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 9 th 2013 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationBeyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer
Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer Wednesday, December 11, 2013 7:30 PM 9:30 PM San Antonio,
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationCurrent Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
More informationEndocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 2012
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationEndocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore
Endocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Outline Guidelines and Evolving Clinical Treatment Landscape for HR+ HER2-
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationClinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
ORIGINAL ARTICLE 2018 Mar 16. [Epub ahead of print] Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Mi Hwa Heo, Hee Kyung Kim,
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationIntroduction. Ahmad Radzi 1*, Fabian Wei Luen Lee 2 REVIEW ARTICLE
doi: 10.18282/amor.v4.i1.255 REVIEW ARTICLE Optimizing treatment-sequencing strategies for the management of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: A
More informationAgents in the Treatment of ER+ Aromatase Inbitor-Resistant Metastatic Breast Cancer: M-THOR Inhibitors
Agents in the Treatment of ER+ Aromatase Inbitor-Resistant Metastatic Breast Cancer: M-THOR Inhibitors Valero, M.D., Professor of Medicine and Deputy Chairman Department of Breast Medical Oncology The
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationBREAST CANCER SLIDE DECK 2017 Selected abstracts from:
BREAST CANCER SLIDE DECK 2017 Selected abstracts from: 2017 ASCO ANNUAL MEETING 2 6 June 2017 Chicago, USA Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the content of this
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationFulvestrant: cuándo y dónde usarlo? Dra. S. López-Tarruella
Fulvestrant: cuándo y dónde usarlo? Dra. S. López-Tarruella FULVESTRANT mechanism of action Carlson et al Clin Breast Cancer 2005; Howell Crit Rev Oncol Hematol 2016; Robertson et al Cancer Res 2001; De
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationCohort D Xentuzumab + abemaciclib + fulvestrant (500 mg/month) Key exclusion criteria RP2D-4 NSCLC. Cohort F Xentuzumab + abemaciclib + fulvestrant
A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy) Douglas
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationKazuhiro Araki, Yasuo Miyoshi
Editorial Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer Kazuhiro Araki, Yasuo
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationLA MALATTIA METASTATICA. La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O.
LA MALATTIA METASTATICA La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O. Narni-Amelia (TR) Outline Re-testing metastatic disease Chemo- vs endocrine-therapy
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationMetastatic HR+ Breast Cancer - CDK 4/6 Inhibitors Charting the Path. Sandy Sehdev MD FRCPC
Metastatic HR+ Breast Cancer - CDK 4/6 Inhibitors Charting the Path Sandy Sehdev MD FRCPC Objectives To understand the approach to the treatment of hormone sensitive metastatic breast cancer and the use
More informationHighlights in breast cancer
CONGRESS HIGHLIGHTS SPECIAL EDITION 309 Highlights in breast cancer W. Lybaert, MD In this article, the most important new studies presented at ESMO 2017 in Madrid in early (EBC) and metastatic breast
More informationOvercoming Endocrine Resistance in ER+ Breast Cancer
Overcoming Endocrine Resistance in ER+ Breast Cancer Richard S. Finn, MD Associate Professor of Medicine Division of Hematology/Oncology Director Signal Transduction and Therapeutics Program Jonsson Comprehensive
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Abemaciclib (Verzenio ) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC) DSD: Horizon Scanning in Oncology
More informationOnline-Only Supplementary Materials
Online-Only Supplementary Materials Online-Only Supplementary Methods: Eligibility Criteria and Study Endpoints and Assessments Supplementary Table 1. Demographic and Baseline Characteristics in Patients
More informationCurrent standards and practice changing studies in Luminal ABC in 2017
Current standards and practice changing studies in Luminal ABC in 2017 F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board
More informationTerapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro
Terapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro Unit of Investigative Clinical Oncology Istituto di Candiolo (IRCCS) Disclosures Speaker s Honoraria
More informationLAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI)
LAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI) Prim Mr Sc Dr Suzana Vasović Institute for oncology and radiology of Serbia UMOS, X Conference, 16.05.2015 Belgrade How do we
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationUpdate mbc. endokrine Therapie
Update mbc endokrine Therapie HR neg ER pos Endokrine Resistenz Endokrine Therapie 1 st line Postmenopause AI/Tam/Fulvestrant 84% AI+ Fulvestrant 33% AI (Tam) + Everolimus 84% AI + CDK4/6 92% Prämenopause
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationBREAST CANCER SLIDE DECK 2017 Selected abstracts from:
BREAST CANCER SLIDE DECK 2017 Selected abstracts from: ESMO 2017 CONGRESS ESMO 2017 CONGRESS 8 12 September 2017 8 12 September Madrid, Spain 2017 Madrid, Spain Supported by Eli Lilly and Company. Eli
More informationNeodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
More informationMONALESSA-7: Phase III placebo-controlled study of ribociclib and tamoxifen/nsai + goserelin
First-line ribociclib or placebo combined with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer:
More informationLOTUS (NCT ) randomized phase II trial
Overall survival update of the double-blind placebocontrolled randomized phase 2 LOTUS trial of firstline ipatasertib + paclitaxel for locally advanced/metastatic triple-negative breast cancer Rebecca
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationNSABP: FB-11. Shannon Puhalla, MD
NSABP: FB-11 Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib with Letrozole as Neoadjuvant Therapy in Post- Menopausal Women with Estrogen Receptor
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationThe TAILORx Trial: A review of the data and implications for practice
The TAILORx Trial: A review of the data and implications for practice Angela DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology University
More informationCase #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer
Case #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer Fellow Presenter: Katherine Clifton, MD Faculty Discussant: Debu Tripathy, MD 7 th Annual June 1, 2018 Topics to Be Discussed: Staging
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationDrafting a Coverage Authorization Request Letter
Drafting a Coverage Authorization Request Letter The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations,
More informationOptimizing therapy selection in ER[+] HER2[-] Advanced Breast Cancer
Optimizing therapy selection in ER[+] HER2[-] Advanced Breast Cancer Dr Antonio Llombart-Cussac, MD, PhD Medical Oncology Division Hospital Arnau Vilanova, Valencia, Spain Disclaimer The contents herein
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationHormonal Management of Metastatic Breast Cancer
Hormonal Management of Metastatic Breast Cancer Dr. Khaled Abulkhair, PhD Medical Oncology SCE, Royal College, UK Ass. Professor of Clinical Oncology Mansoura University, Egypt Case For Discussion A 63
More informationAdvances in the Diagnosis and Treatment of Breast Cancer. Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD
Advances in the Diagnosis and Treatment of Breast Cancer Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD Disclosures Genomic Health: Speaker and Consultant AstraZeneca:
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Everolimus (Afinitor) for Advanced Breast Cancer March 25, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Everolimus (Afinitor) for Advanced Breast Cancer March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationNew chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD
New chemotherapy drugs in metastatic breast cancer Guy Jerusalem, MD, PhD MBC Patients survival over time Median survival increases over time, but is still measured in months This is not yet a chronic
More informationI SOTTOGRUPPI FENOTIPICI E I RISULTATI SINORA RAGGIUNTI. Marta Bonotto Department of Oncology, University Hospital of Udine, Italy
I SOTTOGRUPPI FENOTIPICI E I RISULTATI SINORA RAGGIUNTI Marta Bonotto Department of Oncology, University Hospital of Udine, Italy Breast Cancer Metastatic Breast Cancer (MBC) Metastatic Breast Cancer (MBC)
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 30 OCTOBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationA case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy
ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated
More informationObjectives Primary Objectives:
Z1031 A randomized phase III trial comparing 16 to 18 weeks of neoadjuvant exemestane (25mg daily), letrozole (2.5mg), or anastrozole (1mg) in postmenopausal women with clinical stage II and III estrogen
More informationCDK4 and CDK6 Inhibitor
CDK4 and CDK6 Inhibitor Abemaciclib, LY2835219 Derived from Shapiro GI. 1 Drug Discovery Platform: Cancer Cell Signaling JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More information